Roberto Donini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roberto Donini has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Cleo Kontoravdi
Department of Chemical Engineering, Imperial College London, London, UK
4 shared publications - Stuart M. Haslam
Department of Life Sciences, Imperial College London
3 shared publications - Anja Krueger
Department of Life Sciences, Imperial College London, London, UK
2 shared publications - Karen Marie Polizzi
Department of Chemical Engineering Imperial College London London UK
2 shared publications - Anne Dell
Department of Life Sciences, Imperial College London, London SW7 2AZ, UK
1 shared publication David R. Rose
Department of Biology, University of Waterloo
1 shared publication
Latest Publications
- Open Access
- 16 August 2025
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 122 (11) , 3160-3175
Genetic Divergence and Antibody Expression Influence the N‐Glycomes of CHO‐K1 and CHO‐S Cells
While Chinese hamster ovary (CHO) cells continue to be the workhorse of recombinant therapeutic protein production, decades of genetic divergence in the industrially relevant CHO‐K1 and CHO‐S cell lines, are likely to have resulted in differing glycosylation capabilities. Glycosylation can influence the efficacy, serum half‐life, and safety of biologics, and as a critical quality attribute of glycoprotein biopharmaceuticals, it is essential to better understand how major CHO cell manufacturing platforms diverge. We used matrix‐assisted laser desorption ionization‐time of flight mass spectrometry to perform N‐glycomic analyses comparing CHO‐K1 cells, CHO‐S cells and antibody‐producing daughter cell lines. The results reveal that genetic divergence in these industrially relevant cell lines, as well as the burden of antibody production, lead to significant differences in antennal branching and terminal elaboration in the cellular N‐glycome. More specifically, CHO‐K1 cells produce larger and more complex N‐glycans with higher levels of sialylation than CHO‐S cells, and antibody production was associated with increased antennal branching. Additionally, these findings were also reflected in the N‐glycomic profiles of IgG1‐Fc constructs produced in either CHO‐K1 and CHO‐S cells.
- 16 August 2025
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 122 (11) , 3160-3175
Open AccessGenetic Divergence and Antibody Expression Influence the N‐Glycomes of CHO‐K1 and CHO‐S Cells
While Chinese hamster ovary (CHO) cells continue to be the workhorse of recombinant therapeutic protein production, decades of genetic divergence in the industrially relevant CHO‐K1 and CHO‐S cell lines, are likely to have resulted in differing glycosylation capabilities. Glycosylation can influence the efficacy, serum half‐life, and safety of biologics, and as a critical quality attribute of glycoprotein biopharmaceuticals, it is essential to better understand how major CHO cell manufacturing platforms diverge. We used matrix‐assisted laser desorption ionization‐time of flight mass spectrometry to perform N‐glycomic analyses comparing CHO‐K1 cells, CHO‐S cells and antibody‐producing daughter cell lines. The results reveal that genetic divergence in these industrially relevant cell lines, as well as the burden of antibody production, lead to significant differences in antennal branching and terminal elaboration in the cellular N‐glycome. More specifically, CHO‐K1 cells produce larger and more complex N‐glycans with higher levels of sialylation than CHO‐S cells, and antibody production was associated with increased antennal branching. Additionally, these findings were also reflected in the N‐glycomic profiles of IgG1‐Fc constructs produced in either CHO‐K1 and CHO‐S cells.
- Open Access
- 6 February 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (6) , 732-741
Immobilized enzyme cascade for targeted glycosylation
Glycosylation is a critical post-translational protein modification that affects folding, half-life and functionality. Glycosylation is a non-templated and heterogeneous process because of the promiscuity of the enzymes involved. We describe a platform for sequential glycosylation reactions for tailored sugar structures (SUGAR-TARGET) that allows bespoke, controlled N-linked glycosylation in vitro enabled by immobilized enzymes produced with a one-step immobilization/purification method. We reconstruct a reaction cascade mimicking a glycosylation pathway where promiscuity naturally exists to humanize a range of proteins derived from different cellular systems, yielding near-homogeneous glycoforms. Immobilized β-1,4-galactosyltransferase is used to enhance the galactosylation profile of three IgGs, yielding 80.2–96.3% terminal galactosylation. Enzyme recycling is demonstrated for a reaction time greater than 80 h. The platform is easy to implement, modular and reusable and can therefore produce homogeneous glycan structures derived from various hosts for functional and clinical evaluation.
- 6 February 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (6) , 732-741
Open AccessImmobilized enzyme cascade for targeted glycosylation
Glycosylation is a critical post-translational protein modification that affects folding, half-life and functionality. Glycosylation is a non-templated and heterogeneous process because of the promiscuity of the enzymes involved. We describe a platform for sequential glycosylation reactions for tailored sugar structures (SUGAR-TARGET) that allows bespoke, controlled N-linked glycosylation in vitro enabled by immobilized enzymes produced with a one-step immobilization/purification method. We reconstruct a reaction cascade mimicking a glycosylation pathway where promiscuity naturally exists to humanize a range of proteins derived from different cellular systems, yielding near-homogeneous glycoforms. Immobilized β-1,4-galactosyltransferase is used to enhance the galactosylation profile of three IgGs, yielding 80.2–96.3% terminal galactosylation. Enzyme recycling is demonstrated for a reaction time greater than 80 h. The platform is easy to implement, modular and reusable and can therefore produce homogeneous glycan structures derived from various hosts for functional and clinical evaluation.
- Open Access
Immobilised enzyme cascade for targeted glycosylation
Glycosylation is a critical post-translational modification of proteins, improving properties such as folding, half-life and functionality. However, glycosylation is a non-templated and heterogeneous process because of the promiscuity of the enzymes involved. Here we describe a platform for s eq u ential g lycosyl a tion r eactions for ta ilo r ed su g ar s t ructures (SUGAR-TARGET) that allows bespoke, controlled N-linked glycosylation in vitro . This novel proof-of-concept system is enabled by immobilised enzymes produced with a “one-step immobilisation/purification” method to express, biotinylate in vivo and immobilise glycosyltransferases. The immobilised enzymes are used in a reaction cascade mimicking a human-like N-linked glycosylation pathway where promiscuity naturally exists. The enzyme cascade is applied to free glycans, and a monomeric Fc domain expressed in glycoengineered Pichia pastoris , yielding near homogeneous glycoforms (>95% conversion). Finally, immobilised β-1,4 galactosyltransferase is used to enhance the galactosylation profile of three different IgGs yielding 80.2 – 96.3 % terminal galactosylation. Enzyme recycling was further demonstrated for 7 cycles, with a combined reaction time greater than 140 hours. The novel SUGAR-TARGET platform is easy to implement, modular and reusable, and therefore can lead to the development of homogeneous glycan structures for functional and clinical evaluation. The use of immobilised enzymes enables the economical modification of cell-based material supporting applications at a large industrial scale.
Open AccessImmobilised enzyme cascade for targeted glycosylation
Glycosylation is a critical post-translational modification of proteins, improving properties such as folding, half-life and functionality. However, glycosylation is a non-templated and heterogeneous process because of the promiscuity of the enzymes involved. Here we describe a platform for s eq u ential g lycosyl a tion r eactions for ta ilo r ed su g ar s t ructures (SUGAR-TARGET) that allows bespoke, controlled N-linked glycosylation in vitro . This novel proof-of-concept system is enabled by immobilised enzymes produced with a “one-step immobilisation/purification” method to express, biotinylate in vivo and immobilise glycosyltransferases. The immobilised enzymes are used in a reaction cascade mimicking a human-like N-linked glycosylation pathway where promiscuity naturally exists. The enzyme cascade is applied to free glycans, and a monomeric Fc domain expressed in glycoengineered Pichia pastoris , yielding near homogeneous glycoforms (>95% conversion). Finally, immobilised β-1,4 galactosyltransferase is used to enhance the galactosylation profile of three different IgGs yielding 80.2 – 96.3 % terminal galactosylation. Enzyme recycling was further demonstrated for 7 cycles, with a combined reaction time greater than 140 hours. The novel SUGAR-TARGET platform is easy to implement, modular and reusable, and therefore can lead to the development of homogeneous glycan structures for functional and clinical evaluation. The use of immobilised enzymes enables the economical modification of cell-based material supporting applications at a large industrial scale.
- Open Access
- 11 March 2021
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 49 (2) , 915-931
Glycoengineering Chinese hamster ovary cells: a short history
Biotherapeutic glycoproteins have revolutionised the field of pharmaceuticals, with new discoveries and continuous improvements underpinning the rapid growth of this industry. N-glycosylation is a critical quality attribute of biotherapeutic glycoproteins that influences the efficacy, half-life and immunogenicity of these drugs. This review will focus on the advances and future directions of remodelling N-glycosylation in Chinese hamster ovary (CHO) cells, which are the workhorse of recombinant biotherapeutic production, with particular emphasis on antibody products, using strategies such as cell line and protein backbone engineering.
- 11 March 2021
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 49 (2) , 915-931
Open AccessGlycoengineering Chinese hamster ovary cells: a short history
Biotherapeutic glycoproteins have revolutionised the field of pharmaceuticals, with new discoveries and continuous improvements underpinning the rapid growth of this industry. N-glycosylation is a critical quality attribute of biotherapeutic glycoproteins that influences the efficacy, half-life and immunogenicity of these drugs. This review will focus on the advances and future directions of remodelling N-glycosylation in Chinese hamster ovary (CHO) cells, which are the workhorse of recombinant biotherapeutic production, with particular emphasis on antibody products, using strategies such as cell line and protein backbone engineering.